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Abstract
Background: The prosthesis used for aortic valve replacement in patients with small aortic root
can be too small in relation to body size, thus showing high transvalvular gradients at rest and/or
under stress conditions. This study was carried out to evaluate rest and Dobutamine stress
echocardiography (DSE) hemodynamic response of 17-mm St. Jude Medical Regent (SJMR-17 mm)
in relatively aged patients at mean 24 months follow-up.
Methods and results: The study population consisted of 19 patients (2 men, 17 women, mean
age 69.2 ± 7.3 years). All patients underwent rest Doppler echocardiography before and after
surgery and basal and DSE at follow up (infused at rate of 5 micrg/Kg/min and increased by 5
microg/Kg/min at 5 min intervals up to 40 microg/Kg/min). The following parameters were
evaluated at rest and/or under DSE: heart rate (HR), ejection fraction (EF), cardiac output (CO),
peak and mean velocity and pressure gradients (MxV, MnV, MxPG, MnPG), effective orifice area
(EOA), indexed EOA (EOAi), left ventricular mass (LVM), indexed LVM (LVMi), Velocity Time
Integral at left ventricular outflow tract (VTI LVOT) and transvalvular (Aortic VTI), Doppler
velocity index (DVI). At rest MxPG and MnPG were 29.2 ± 7.1 and 16.6 ± 5.8mmHg, respectively;
EOA and EOAi resulted 1.14 ± 0.3 cm2 and 0.76 ± 0.2 cm2/m2; DVI was normal (0.50 ± 0.1). At
follow-up LVM and LVMi decreased significantly from pre-operative value of 258 ± 43g and 157.4
± 27.7g/m2 to 191 ± 23.8g and 114.5 ± 10.6g/m2, respectively. DSE increased significantly HR, CO,
EF, MxGP (up to 83.4 ± 2 1.9mmHg), MnPG (up to 43.2 ± 12.7mmHg). EOA, EOAi, DVI increased
insignificantly (from baseline up to 1.2 ± 0.4 cm2, 0.75 ± 0.3cm2/m2 and 0.48 ± 0.1 respectively).
Two patients developed significant intraventricular gradients.
Conclusion: These data show that SJMR 17-mm prostheses can be safely implanted in aortic
position in relatively aged patients, offering a satisfactory hemodynamic performance at rest and
under DSE, with full utilization of its available orifice, suggesting that a possible mild prosthesis-
patient mismatch is not an issue of clinical relevance when this small prosthesis is used. Rest and
Dobutamine stress echocardiography is a useful and effective means for evaluating prosthesis
hemodynamics and for monitoring the expected LVH regression.
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Background
Patients who have received prosthetic heart valves are usu-
ally followed by clinical evaluation and basal echocardio-
graphic examinations [1,2]. Patients who receive a small
aortic valve prosthesis may remain asymptomatic follow-
ing surgery and Doppler echocardiography may show
normal or mild elevated transvalvular gradients at rest,
even in patients with large body surface area (BSA) [1-5].
However, this may not be representative of a patient's
daily activities. Evaluation of valve hemodynamic
response during stress conditions may offer useful infor-
mation, simulating preclinical valve "dysfunction"
[2,6,7]. Information derived from exercise stress echocar-
diography is limited because of the difficulty in obtaining
adequate Doppler signals either due to the respiratory-
related artefacts or to the increased chest wall motion dur-
ing or immediately after exercise [2,6,7]. Recently, dob-
utamine stress echocardiography (DSE) has been
proposed as an alternative and equally effective means for
the hemodynamic evaluation of small aortic prosthetic
valves [8-15]. This pharmacological test does not have the
above limitations. This study was carried out to evaluate
rest and DSE hemodynamic response of 17 mm St. Jude
Medical Regent (SJMR-17 mm) aortic prosthesis in rela-
tively aged patients. The SJM Regent is a new-generation
mechanical heart valve that represents the design evolu-
tion of the St. Jude Hemodynamic Plus (SJM HP) series. It
is constructed of pyrolytic carbon which has a modified
external profile that achieves a larger geometric orifice
area without changing the existing design of the pivot
mechanism or blood-contact surface area. The SJMR-17
mm valve, having a large actual (nominal) orifice area
(AOA) as provided by manufacturer equivalent to a stand-
ard valve one size larger, seemed appropriate to be
implanted and evaluated in relatively aged patients with
aortic valve stenosis and small aortic root, where other
alternatives, such as annulus enlargement, in order to
make space for a larger valve prosthesis were not suitable
because of the increased operative risk.
Methods
Patient population
The study population consisted of nineteen consecutive
patients of mean age 69.2 ± 7.3 years (2 men, 17 women),
who 36 ± 12 months before had received a SJMR-17 mm
aortic valve, after sizing the aortic annulus and deciding
not to attempt to enlarging it. This cohort represents 7%
of patients (19/265) who underwent aortic valve replace-
ment (AVR) over four years at our Centre. AVR had been
performed for rheumatic or degenerative valve disease
resulting in severe stenosis. In one patient with degenera-
tive mitral valve disease and moderate-severe valvular
regurgitation concomitant valve replacement had been
performed and in two patients with significant CAD single
coronary artery by-pass grafting. Four patients with degen-
erative mitral valve disease and less than moderate mitral
regurgitation had been treated with AVR alone. All
patients but one were in sinus rhythm at the time of the
study; none had had a myocardial infarction or angina
pectoris after the operation. Demographic data are sum-
marized in Table 1. All patients underwent basal echocar-
diography before cardiac surgery and 1 month after
surgery and were controlled every year by clinical exami-
nations. At mean distance of 24 months after surgery
patients were enrolled in the study and underwent rest
echocardiography and DSE. Beta-blockers were discontin-
ued in all patients 24 hours before the test, whilst patients
on ace-inhibitors and calcium antagonists continued their
medication. Informed written consent was obtained from
all patients.
Study protocol
All studies (pre-operative, post-operative and follow-up)
were performed with the use of 2.5–3.5 MHz transducer
interfaced to the SONOS 5500 (Agilent Technologies,
Andover, Mass) by same physicians (G.M., C.M., G.P.).
The baseline study with standard M-Mode and 2-D meas-
urements was completed according ASE criteria [16] and
left ventricular mass (LVM) as well as left ventricular mass
index (LVMi) were measured. Dobutamine was then
infused intravenously starting at 5 microg/Kg/min and
increased by 5 microg/Kg/min at 5 min intervals up to 40
microg/Kg/min. The DSE was terminated if any of the fol-
lowing end-points were met: (1) target heart rate >85% of
maximal predicted, (2) angina or progressive dyspnoea,
(3) 2-mm ST-segment depression 80 msec after the J
point, (4) hypertension (systolic blood pressure >220,
diastolic blood pressure >120 mmHg), (5) hypotension
(drop in systolic blood pressure >30 mmHg), (6) frequent
Table 1: Demographic and Clinical variables.
Variables N° (%)
Females/males 17/2
Mean age (years) 69.2 ± 7.3
Mean Body Surface Area (m2) 1.68 ± 0.2
Mean Body Mass Index (Kg/m2) 24.6 ± 7.5
Diabetes 4 (21)
Coronary Artery Disease history 4 (21)
Hypertension 8 (42)
Hypothyroidism 2 (10.5)
Smoking history 5 (26.3)
Previous Transient Ischemic Attack 4 (21)
Previous carotid endarterectomy 1 (5.2)
Peripheral vascular disease 2 (10.5)
Atrial fibrillation 1 (5.2)
Chronic obstructive pulmonary disease 4 (21)
Mean New York Heart Association Functional class 2.75 ± 0.86
Mean Canadian cardiovascular Class 1.63 ± 0.72
Left ventricular ejection fraction <35% 1 (5.2)
Mitral valve disease 5 (26.3)Journal of Cardiothoracic Surgery 2006, 1:27 http://www.cardiothoracicsurgery.org/content/1/1/27
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or polymorphous ventricular ectopic beats, (7) supraven-
tricular tachyarrhythmias. Heart rate (HR) and a 12-lead
ECG were recorded continuously; blood pressure, ejection
fraction (EF), cardiac output (CO), peak and mean pres-
sure gradients (MxPG, MnPG), effective orifice area
(EOA), effective orifice area index (EOAi) as well as Dop-
pler velocity index (DVI) were measured at baseline and at
the end of each increment of dobutamine.
Measurements and calculations
The MxPG across the prosthesis was estimated by the
modified Bernoulli equation (4 V2); the MnPG was
derived by planimetry of the Doppler envelope. Measure-
ments from at least three velocity envelopes were averaged
to assure consistency. The EOA was calculated by the con-
tinuity equation: EOA (cm2)= CSA LVOT × V LVOT inte-
gral/V Transprosthetic integral, where CSA is cross-
sectional area, LVOT is left ventricular outflow tract, and V
is velocity integral. Assuming a circular shape, the CSA
LVOT was calculated as: 3.14 × (D/2)2, where D is the
inner diameter of the left ventricular outflow tract. The V
LVOT was obtained with pulsed-wave Doppler in the left
ventricular outflow tract proximal to the aortic prosthesis
from the apical five-chamber view; the V Transprosthetic
was obtained with continuous-wave Doppler from the
apical five-chamber view. The EOAi was calculated by the
formula EOA/BSA (body surface area). LVM was derived
from Devereux's formula and LVMi from LVM/BSA. The
DVI was calculated by the formula: V integral LVOT/V
integral transprosthetic (normal value >0.40). The CO
was derived from the formula: stroke volume (CSA × V
LVOT integral) X HR.
Statistical analysis
Group statistics were expressed as mean ± SD. Paired Stu-
dent's test was used to measure the variations of the
parameters documented between baseline and follow-up.
The non-linear relation between mean trans-prosthetic
gradients at rest and EOAi was analysed by means of scat-
terplots and exponential curve estimation regression sta-
tistics. All analyses were performed by using SPSS 11.0
statistical software. A p value < 0.05 was considered signif-
icant.
Results
Pre-operative and post-operative echocardiographic data
are reported in Table 2. At the time of the study the mean
NYHA class was significantly lower than pre-operatively
(1.3 ± 0.6 vs 2.75 ± 0.86, p < 0.001). The basal transpros-
thetic mean and maximal flow velocities were, respec-
tively, 1.7 ± 0.2 and 2.6 ± 0.3 m/sec; consequently MnPG
and peak MxPG were 16.6 ± 5.8 and 29.2 ± 7.1 mmHg;
EOA and EOAi resulted 1.14 ± 0.3 cm2 and 0.76 ± 0.2
cm2/m2; DVI was normal (0.50 ± 0.1) (Table 3). A non-
linear relation between mean transprosthetic gradient at
rest and EOAi was found, being patients with EOAi <0.85
cm2/m2 on the steep portion of the curve, where gradients
are relatively high (Figure 1). LVM and LVMi decreased
from pre-operative values of 258 ± 43g and 157.4 ± 27.7g/
m2 to 191 ± 23.8g and 114.5 ± 10.6 g/m2, respectively (p
< 0.00001 and <0.0001) (Figure 2). Individual data
regarding a possible link between rest and stress gradients,
EOAi and regression of hypertrophy are reported in Table
4. All patients completed DSE without complications.
Four patients had occasional premature atrial and/or ven-
tricular beats, which did not preclude them from complet-
ing the test. With dobutamine, HR increased from a
baseline of 64.5 ± 10 to 100.6 ± 28 beats/min (p < 0.001);
CO increased from a baseline of 4.7 ± 1.6 L/min to 8.2 ±
2 L/min (p < 0.0001); EF increased from a baseline of 58.4
± 8% to 68 ± 9.9% (p < 0.008). Basal systolic and diastolic
blood pressure did not change significantly during test,
whilst the double product increased significantly. At peak
dobutamine, the mean and maximal flow velocities
increased from baseline to 2.9 ± 0.4 and 4.5 ± 0.5 m/sec.,
respectively (p < 0.0001 and <0.0001); the MnPG and
Table 2: Pre- and post-operative echocardiographic data.
Variables before surgery after surgery p-value
BSA m2 1.6 ± 0.2
LVOT mm 17.5 ± 1.5
Effective Orifice Area (cm2) 0.6 ± 0.2 1.1 ± 0.3 <0.0001
Indexed Effective Orifice Area (cm2/m2) 0.36 ± 0.9 0.7 ± 0.2 <0.0001
Maximal velocity (m/sec) 4.6 ± 0.6 2.7 ± 0.4 <0.0001
Mean velocity (m/sec) 3.6 ± 0.5 1.8 ± 0.3 <0.0001
Maximal gradient (mmHg) 88.2 ± 20.3 32.6 ± 11.3 <0.0001
Mean gradient (mmHg) 53.5 ± 13.6 16.6 ± 5.8 <0.0001
VTI LVOT (cm) 25.5 ± 6.9 27.45 ± 9.6 NS
VTI transvalvular (cm) 105.3 ± 20.1 57.2 ± 15.79 <0.0001
Doppler Velocity Index 0.24 ± 0.1 0.47 ± 0.1 <0.0001
Left Ventricular Mass (g) 258 ± 43 NA
Indexed Left Ventricular Mass (g/m2) 157.4 ± 27.7 NAJournal of Cardiothoracic Surgery 2006, 1:27 http://www.cardiothoracicsurgery.org/content/1/1/27
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MxPG increased significantly from baseline, achieving,
respectively, 43.2 ± 12.7 and 83.4 ± 21.9 mmHg (p <
0.0001 and p < 0.0001). EOA, EOAi and DVI changed
during the test. At peak dobutamine, these parameters had
an insignificant increase, EOA and EOAi from baseline to
stress 1.2 ± 0.4 cm2 and 0.75 ± 0.3 cm2/m2 (p = 0.34 and
0.45) respectively, the DVI from baseline to stress 0.48 ±
0.1 (p = 0.72). Changes of all parameters are summarized
in Table 3. Two out of the 19 patients developed signifi-
cant subvalvular or intraventricular gradients during DSE.
The mean NYHA class did not change significantly during
the test or soon after.
Discussion
Two-dimensional and Doppler echocardiography is an
accurate, reliable and non invasive tool for assessing pros-
thetic heart valves [1,2]. However, the ideal means for test-
ing valve function requires rest and stress hemodynamic
evaluation, under various flow conditions [2,6]. Recently,
DSE has been proposed as an alternative means for evalu-
ating valve hemodynamics [8-15]. In this study we used
basal and dobutamine 2-dimensional and Doppler
echocardiography for assessing aortic SJMR-17 mm pros-
theses, implanted in patients with a small aortic root, the
use of which is controversial because of the small orifice
area. In our experience SJMR-17 mm prostheses showed
rest mean and peak gradients of 16.6 ± 5.8 and 29.2 ± 7.1
mmHg similar to the gradients reported in literature for
SJM standard or HP valves of larger sizes (19–21 mm),
respectively of 17.2 ± 3.3 and 33 ± 4 mmHg
[4,9,11,12,15,18,19], and slightly higher when compared
to other larger (21–23 mm) bileaflet mechanical valves,
respectively of 15 ± 2.6 and 27.7 ± 4 mmHg [4,5,9,12-15],
although there was a large overlap between the values of
these variables. When we compared EOA and EOAi of
SJMR-17 mm with the reported results of larger (19–23
mm) mechanical valves, we found values slightly lower
respectively 1.14 ± 0.3 cm2 vs 1.21 ± 0.19 cm2 and 0.76 ±
0.2 cm2/m2 vs 0.88 ± 0.2 cm2/m2. The finding of average
EOAi < 0.85 cm2/m2 might suggest that the majority of
patients had a mild prosthesis-patient mismatch (PPM)
[17]. During DSE mean and peak flow velocity, and mean
and peak gradients rose markedly. Similar results were
obtained in previous studies which evaluated prosthetic
valves of different types and sizes under stress conditions,
induced by exercise or dobutamine echocardiography
[4,9,11-15]. These studies clearly demonstrated a strong,
inverse correlation between prosthetic size and basal and
stress gradients, namely smaller valves with more elevated
mean and peak gradients. Large BSA and young age have
also been considered as predictors of unfavorable hemo-
dynamics [5,11,12,17]. The relation between BSA and gra-
dients is still controversial [5,11,12]. No correlation was
found in our study. Young age (<50 years), especially in
patients who are physically active, has been reported as
predictor of potential PPM [11,12]. It has therefore been
suggested [11,13,14,20] that in patients requiring a 19
mm valve or smaller, prostheses with the largest actual
(nominal) orifice area (AOA) as provided by manufac-
turer, or other types of valve prostheses, i.e. stentless por-
cine [4,13,14,21-25], aortic homograft [24] or pulmonary
autograft [22,23] should be considered. As an alternative
patients could be subjected to an aortic root enlargement
procedure [25]. However, the increased operative risk of
this procedure must be considered. In our study BSA and
age of patients were 1.68 ± 0.2 m2 and 69.2 ± 7.3 years,
respectively and SJMR-17 mm prostheses, having an AOA
equivalent to a standard valve one size larger, seemed
Pre- and post-operative left ventricular mass index values in  individual patients (LVMi pre and post) Figure 2
Pre- and post-operative left ventricular mass index values in 
individual patients (LVMi pre and post).
Relation between mean transprosthetic gradient at rest and  indexed effective orifice area Figure 1
Relation between mean transprosthetic gradient at rest and 
indexed effective orifice area.Journal of Cardiothoracic Surgery 2006, 1:27 http://www.cardiothoracicsurgery.org/content/1/1/27
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appropriate. Our patients are older than those usually
enrolled in published studies, in which the mean age is
62.5 ± 5.5 years [4,5,8-13,15]. The transprosthetic valve
gradient depends on the valve type and size, the diastolic
filling period, and the ventricular loading conditions.
Therefore, it should be noted that high gradients do not
necessarily mean prosthetic stenosis. Since the volumetric
flow in the outflow tract equals the volumetric flow
through the prosthetic valve (Q LVOT=Q prosthesis), the
rise in cardiac output generated by DSE increases the flow
velocities on the two sides of the valve orifice, maintain-
ing the EOA basically unchanged [9,26]. This principle of
conservation of mass was clearly demonstrated in our
study when the continuity equation (Q LVOT × A LVOT=
Q transprosthetic × A transprosthetic) was applied at base-
line and at peak stress: the aortic valve area remained rel-
atively unchanged despite a significant increase in
transprosthetic gradients. Such a finding is highly
expected as mechanical valves, because of their stiff com-
ponents, are less prone to accommodating larger stroke
volume by increasing their effective area. These results
confirm previous data derived from patients with larger
size mechanical aortic prosthesis [4,9,11-15], suggesting
that a mild-moderate PPM could not always be an issue of
Table 4: Rest and peak gradients, indexed effective orifice area and regression of left ventricular hypertrophy in individual patients.
Patient Rest Max PG 
(mmHg)
Rest Mean PG 
(mmHg)
Stress Max PG 
(mmHg)
Stress Mean PG 
(mmHg)




1 29,00 15,00 50,00 23,00 0,63 -115
2 16,00 6,90 51,00 22,50 1,39 -126
3 35,50 17,30 50,00 28,00 0,47 -7
4 39,40 19,10 48,00 24,00 0,54 -33
5 62,70 31,80 65,00 30,00 0,83 -50
6 14,00 7,70 40,00 21,00 1,05 -40
7 44,10 26,30 58,00 28,00 0,65 8
8 29,00 15,00 45,00 22,00 0,63 -65
9 38,00 18,00 45,00 30,00 0,61 0
10 29,00 14,00 113,00 58,00 0,98 -17
11 35,00 19,00 83,00 44,00 0,49 -60
12 35,00 19,00 72,00 32,00 0,62 -39
13 30,00 15,00 114,00 58,00 0,55 -18
14 42,00 20,00 93,00 39,00 0,81 -39
15 28,00 16,00 65,00 38,00 0,84 -34
16 23,00 11,00 101,00 59,00 0,75 -28
17 25,00 14,00 62,00 33,00 0,83 -20
18 29,00 15,00 73,00 41,00 0,48 -76
19 35,00 17,00 63,00 28,00 0,71 -21
EOA: Effective orifice area; PG: pressure gradient; LVMi: left ventricular mass index
Table 3: Echocardiographic data at rest and under DSE at follow up.
Variables at rest under peak stress p-value
Effective Orifice Area (cm2) 1.14 ± 0.3 1.2 ± 0.4 NS
Indexed Effective Orifice Area (cm2/m2) 0.76 ± 0.20 0.75 ± 0.3 NS
Maximal velocity (m/sec) 2.6 ± 0.3 4.5 ± 0.5 <0.0001
Mean velocity (m/sec) 1.7 ± 0.2 2.9 ± 0.4 <0.0001
Maximal gradient (mmHg) 29.2 ± 7.1 83.4 ± 21.9 <0.0001
Mean gradient (mmHg) 16.6 ± 5.8 43.2 ± 12.7 <0.0001
Doppler Velocity Index 0.50 ± 0.1 0.48 ± 0.1 NS
VTI LVOT (cm) 32.1 ± 10.5 34.2 ± 7.7 NS
VTI transprosthetic (cm) 62.8 ± 13.7 72.5 ± 17.3 0.032
Left Ventricular Ejection Fraction 58.4 ± 8 68 ± 9.9 <0.008
Cardiac Output (L/min) 4.7 ± 1.6 8.2 ± 2 <0.0001
Heart rate (b/min) 64.5 ± 10 100.6 ± 28 <0.001
Systolic pressure (mmHg) 139 ± 23 152 ± 26 NS
Diastolic pressure (mmHg) 77 ± 10.6 77 ± 12.5 NS
Double Product 8978 ± 2184 15225 ± 5147 <0.0001
Left Ventricular Mass (g) 191 ± 23.8 NA
Indexed Left Ventricular Mass (g/m2) 114 ± 10.6 NAJournal of Cardiothoracic Surgery 2006, 1:27 http://www.cardiothoracicsurgery.org/content/1/1/27
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clinical relevance[17]. Some authors have found that PPM
leads to higher mortality rates[17], others have found no
effects on overall mortality[27,28], but its clinical impact
probably seems to be related to both severity of LV work-
load and function, thus suggesting the fact that a diseased
ventricle is much more sensitive to increased after-
load[17]. The DVI, which is a further guide to valve orifice
behaviour, independent of measurement of LVOT diame-
ter [29], has been evaluated only in few studies [15,30]. In
our study it remained substantially unchanged during
stress, according to EOA and EOAi. During dobutamine
infusion CO, EF, HR and double product increased signif-
icantly, confirming published data [4,9,12,13,15].
The influence of prosthesis size on change in LVM
remains controversial [5,31-33]. Some studies found a
strong correlation between prosthetic size and left ven-
tricular hypertrophy (LVH) regression [5,17,18,31], oth-
ers did not support this finding [32,33]. Moreover, other
studies found that the degree of mass regression may vary
markedly from one patient to another[17]. In this series
the LVM and LVMi decreased significantly from pre-oper-
ative, returning to a normal range. Thus the SJMR-17 mm
prosthesis, which increases EOA of the aortic valve and
consequently reduces the pressure gradient, probably
eliminates one of the factors stimulating LVH. These find-
ings seem to confirm the positive effect of AVR on LVH
irrespective of prosthesis size and of mild PPM. Further-
more, the increase in maximal and mean trans-prosthetic
gradients during DSE, which mimics stress conditions of
patient's daily activities, seems to be without clinical
importance in this sample population, represented how-
ever by relatively aged patients. Two patients who had iso-
lated AVR developed significant dynamic outflow
obstruction during DSE, without clinical symptoms. This
phenomenon has been observed in patients with proven
or suspected CAD [34-36] (prevalence of 3.8–7.5%) or in
patients who have undergone concomitant mitral valve
repair [37]. The suspected mechanisms are: increased
myocardial contractility, decreased venous return to the
left ventricle, mitral valve systolic anterior motion or
peculiar characteristics of left ventricular geometry. This
finding was detected in up to 60% of patients with a small
aortic prosthesis by Hunziker et al. [11], but has not been
confirmed by other studies [4,9,12-14]. To our knowl-
edge, this is the first report dealing with patients with 17
mm prosthetic aortic valves. The use of dobutamine as in
our protocol was not associated with side effects, confirm-
ing previous data [9]. It would appear that this test can be
safely used in relatively aged patients, which represent a
growing population requiring aortic valve replacement.
An additional advantage of using the "full" protocol is the
ability to assess coronary artery disease, by analysis of left
ventricle segmental wall motion under stress conditions.
Limitations of the study
The small number of patients examined demonstrates the
rarity of patients potentially requiring a 17 mm aortic
valve prosthesis. In this experience the 17 mm aortic valve
prosthesis was implanted in relatively aged patients, older
than those usually enrolled in published studies. It is
therefore difficult to differentiate the hemodynamic
response in younger patients who have a more active life.
Methodologically, a major limitation of continuous-wave
Doppler is the possibility of overestimating valvular flow
velocity and pressure gradients and underestimating the
valve area by continuity equation, as a consequence of
pressure-recovery phenomenon. Since the rest and dob-
utamine prosthetic assessment are both subject to the
same limitation, the ensuing intra-individual comparison
that follows is statistically valid.
Conclusion
In relatively aged patients with a small aortic root, the
SJMR-17 mm valves can be implanted, because of their
satisfactory hemodynamic profile at rest and under phar-
macological stress conditions. Basal and dobutamine
echocardiography is a useful and effective means for eval-
uating prosthesis hemodynamics (gradients, EOA, DVI
and indexed values) and for monitoring the expected LVH
regression. A standard methodology for studying aortic
prostheses in basal conditions, using these echocardio-
graphic paramethers, is warranted.
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